Loading...
NPI 1356009245 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Az Labs Limited is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 4 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Az Labs Limited |
| Address | 4801 W Peterson Ave Ste 215 |
| City | Chicago |
| State | IL |
| ZIP | 60646 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 8, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $12.8M |
| Medicaid | $255.6K |
AZ LABS LIMITED is operating as a clinical medical laboratory with an overwhelming emphasis on COVID-19 testing codes: its Medicare portfolio is dominated by K1034 (provision of nonprescription self-administered COVID-19 tests) which alone generated $12.5M and represents 97.1% of the provider's Medicare revenue, and the related molecular and specimen-collection codes U0003, U0005 and G2023 together with K1034 form the top revenue mix. This code mix indicates the operation is principally configured to distribute and process high-volume COVID-19 tests rather than a broad panel of clinical laboratory services.
Revenue concentration is extreme for both payers: the top 3 Medicare codes account for 99.5% of the provider's $12.8M Medicare revenue, and the top 3 Medicaid codes account for 98.9% of its $255.6K Medicaid revenue. These figures signal that AZ LABS has a very narrow service and revenue base with near-total dependence on a small set of COVID-19 testing codes.
The provider is effectively Medicare-dominant in scale: reported lifetime Medicare revenue is $12.8M compared with $255.6K in Medicaid. This large disparity makes AZ LABS functionally single-payer-dominant from a revenue perspective, with Medicaid representing only a small fraction of total reported public-payer volume.
K1034 is a statistical outlier nationally for Medicare: K1034 has 1M claims, $12 avg paid/claim, $12.5M revenue and ranks #42 of 30143 providers (100th percentile; extreme outlier, far above typical national volume for this code). That national standing indicates AZ LABS is a major, atypically large participant in the nonprescription self-administered COVID-19 test supply chain relative to virtually all peers.
Competing presence on molecular test codes is modest-to-typical: Medicare U0003 (3K claims, $224.7K revenue) ranks #80 of 973 providers (92th percentile; typical, unremarkable volume), U0005 (3K claims, $75.3K) ranks #101 of 1090 (91th percentile; typical, unremarkable volume), and G2023 (3K claims, $69.9K) ranks #60 of 465 (87th percentile; typical, unremarkable volume). These ranks imply AZ LABS participates at a normal-activity level for laboratory nucleic acid SARS-CoV-2 testing rather than as a dominant national lab for these specific molecular services.
In the Medicaid market the pattern is similar but scaled down: Medicaid U0003 accounts for $152.5K (59.7% of the provider's Medicaid revenue) and ranks #94 of 350 in-state (73th percentile; typical, unremarkable volume), while U0005 ($51K, 20.0%) and G2023 ($49.3K, 19.3%) are also typical in-state participants. The Medicaid code rank-percentiles indicate AZ LABS is a routine state-level provider for molecular and specimen-collection COVID-19 services rather than a market leader.
Tenure is relatively recent: the NPI was enumerated on 2021-12-08 (~5 years ago), indicating the entity has been active for a short-to-moderate period consistent with COVID-era laboratory entrants and growth driven by pandemic testing demand. That timing helps explain both the rapid accumulation of COVID-focused revenue and the concentrated code mix.
From a payer/competitive-analytics standpoint, AZ LABS presents as a highly specialized COVID-testing operator with national-scale volume for K1034 (an extreme outlier) and otherwise typical participation in other SARS-CoV-2 testing codes. For payers and analysts, risk or opportunity assessments should focus on the consequences of this narrow revenue base—any shifts in demand, coverage, or coding for these COVID-19 services would likely have outsized impact on the provider's financial profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,039,100 | $10 | $12.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,040 | $70 | $224.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3,010 | $30 | $75.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,040 | $20 | $69.9K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,680 | $60 | $152.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,690 | $20 | $51K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,740 | $20 | $49.3K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,390 | $1 | $2.8K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 94 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 63 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 71 | 400 | 550 | $20 | $90.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 20 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Az Labs Limited, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Rainbow Lab Inc | IL | Clinical Medical Laboratory | $15.1M | $9.7M |
| S K Diagnostics Inc | IL | Clinical Medical Laboratory | $21.4M | $20.3K |
| Cl Labs Inc. | IL | Clinical Medical Laboratory | $166.5K | $11M |
| Safeena Enterprises Inc | IL | Clinical Medical Laboratory | $8.6M | $0 |
| Chicago Department Of Public Health | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $6.2M |
| Aza Labs Inc | IL | Clinical Medical Laboratory | $1M | $5M |
| County Diagnostic Incorporation | IL | Clinical Medical Laboratory | $5.3M | $92.8K |
| Abdulmassih Abdulmassih | IL | Family Medicine Physician | $374.7K | $3.3M |
| Kyriaki Ades | IL | Dentist | $0 | $3.6M |
| Aim One Incorporated | IL | Durable Medical Equipment & Medical Supplies | $0 | $3.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.